

## Supplementary information – Table of contents

**Table S1.** Commercial products used in this study.

**Table S2.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of BNT162b2 group (n = 6).

**Table S3.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of mRNA-1273 group (n = 16).

**Table S4.** Comparison of mean titers in mRNA-1273 group participants based on a history of previous COVID-19.

**Table S5.** Quantitative titers on each assay in patients on biologics/immunosuppressants.

**Fig. S1.** Box-whisker plots demonstrating the spread of only positive quantitative (titer) results for each vaccine group for the (a) RBD IgG assay; (b) Trimeric S IgG assay; and (c) nAb assay.

**Table S1.** Commercial products used in this study.

Item	Description	Commercial affiliation
BNT162b2 vaccine	mRNA vaccine	Pfizer (New York, NY, USA)
mRNA-1273 vaccine	mRNA vaccine	Moderna Messenger Therapeutics (Cambridge, MA, USA)
Serology assay (Abbott Architect)	SARS-CoV-2 IgG targeting the nucleocapsid protein	Abbott (Chicago, IL, USA)
Serology assay (Abbott Architect)	SARS-CoV-2 IgG targeting the receptor binding domain (RBD)	Abbott (Chicago, IL, USA)
Serology assay (DiaSorin Liaison)	SARS-CoV-2 IgG targeting the S1/S2 regions of the spike protein	DiaSorin (Saluggia, Italy)
Serology assay (manual assay)	SARS-CoV-2 neutralizing antibody (nAb) preventing RBD and angiotensin- converting enzyme 2 (ACE- 2)	GenScript (Piscataway, NJ, USA)
Electronic medical record (EMR)	Epic EMR	Epic (Verona, WI, USA)
Statistical software	Stata Version 16.1	StataCorp (College Station, TX, USA)

**Table S2.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of BNT162b2 group (n = 6).

Case	Days between COVID-19 diagnosis and first vaccine dose <sup>a</sup>	Anti-N IgG result at baseline <sup>b</sup>	Anti-N IgG result 2-weeks post first dose of vaccine	Anti-N IgG result prior to second dose of vaccine
Case 1	27	+	+	ND
Case 2	45	+	+	+
Case 3	46	+	-	ND
Case 4	118	+	+	ND
Case 5	-7	-	ND	+
Case 6 <sup>c</sup>	-34	-	-	-

Abbreviations: ND – not done; + positive; - negative

<sup>a</sup>A negative value refers to the diagnosis of COVID-19 being made after the first dose of vaccine. All SARS-CoV-2 diagnosis were confirmed using PCR testing from a nasopharyngeal or oropharyngeal swab collected due to symptoms.

<sup>b</sup>Qualitative results on the RBD IgG, Trimeric S IgG, and GenScript nAb assays were concordant with the Anti-N IgG result at baseline for all six cases.

<sup>c</sup>Confirmed COVID-19 positive nine days after second dose of BNT162b2 vaccine.

**Table S3.** Anti-Nucleocapsid IgG detection in relation to history of confirmed laboratory diagnosis of SARS-CoV-2 infection in participants of mRNA-1273 group (n = 16).

Case	Days between COVID-19 diagnosis and first vaccine dose <sup>a</sup>	Anti-N IgG result 2-weeks post first vaccine dose <sup>b</sup>	Anti-N IgG result prior to 2 <sup>nd</sup> dose of vaccine <sup>b</sup>
Case 1	18	+	ND
Case 2	18	ND	ND
Case 3	22	ND	ND
Case 4	27	+	+
Case 5	34	ND	+
Case 6	35	ND	ND
Case 7	41	ND	-
Case 8	41	ND	ND
Case 9	45	+	+
Case 10	45	ND	ND
Case 11	48	ND	ND
Case 12	73	+	+
Case 13	73	+	-
Case 14	73	-	-
Case 15	76	+	-
Case 16	76	ND	+

Abbreviations: ND – not done due to shortage of assay reagents ; + positive; - negative

<sup>a</sup>All SARS-CoV-2 diagnosis were confirmed using PCR testing from a nasopharyngeal or oropharyngeal swab collected due to symptoms.

<sup>b</sup>All of these patients were found to be positive in one or more of either RBD IgG, Trimeric S IgG, or nAb titer.

**Table S4.** Comparison of median titers (IQRs) in mRNA-1273 group participants based on a history of previous COVID-19.

Time point	Assay	COVID-19 Recovered	No prior history of COVID-19	p-value
2-weeks post first vaccine dose	Trimeric S-IgG (AU/mL)	785 (640-800) (n = 7)	14.4 (0-40.3) (n = 25)	0.0002
	RBD IgG (AU/mL)	40,000 (28,534.6-40,000) (n = 7)	74.7 (3.6-429.7) (n = 25)	<0.0001
	nAb (ng/mL)	37,672 (1,233.8-107,194.2) (n = 7)	0 (0-189.6) (n = 25)	0.0009
Pre-2 <sup>nd</sup> vaccine dose	Trimeric S-IgG (AU/mL)	800 (651-800) (n = 16)	58.2 (13.8-113) (n = 31)	<0.0001
	RBD IgG (AU/mL)	40000 (37257.3-40000) (n = 9)	280.9 (88.1-909.5) (n = 28)	<0.0001
	nAb (ng/mL)	33,874.2 (2,179.4-48,052.8) (n = 16)	185.4 (0-386.2) (n = 32)	<0.0001

**Table S5.** Quantitative titers on each assay in patients on biologics/immunosuppressants.


Timing of blood sample / Assay	Participant 1 (BNT162b2)	Participant 2 (BNT162b2)	Participant 3 (BNT162b2)	Participant 4 (BNT162b2)	Participant 5 <sup>a</sup> (mRNA-1273)
Baseline blood sample					
RBD IgG (AU/mL)	6.8	0	0	0	ND
Trimeric S IgG (AU/mL)	1.9	1.9	1.9	1.9	ND
nAb (ng/mL)	0	0	0	0	ND
2-week blood sample					
RBD IgG (AU/mL)	270.6	127.4	492.9	641.4	7,541.3
Trimeric S IgG (AU/mL)	56.3	17.4	119	139	371
nAb (ng/mL)	0	0	477	250.2	2,534.2
Pre-2 <sup>nd</sup> dose blood sample					
RBD IgG (AU/mL)	ND	247.2	ND	1,092.8	8,210.6
Trimeric S IgG (AU/mL)	ND	23.4	ND	162	428
nAb (ng/mL)	ND	281.4	ND	540.2	3,020.4

Abbreviations: ND – not done.


<sup>a</sup>Participant 5 is COVID-19 recovered (received first dose of mRNA-1273 vaccine 73 days post date of COVID-19 diagnosis).

**Figure S1:**


**a**



**b**



**c**



**Fig. S1.** Box-whisker plots demonstrating the spread of only positive quantitative (titer) results for each vaccine group for the (a) RBD IgG assay; (b) Trimeric S IgG assay; and (c) nAb assay.